Drug intelligence / Profile preview

VNX-301

Development stage: Preclinical
Lead developer: Vironexis Biotherapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

VNX-301 is an investigational AAV-delivered T-cell immuno-gene therapy being developed by Vironexis Biotherapeutics for the treatment of nasopharyngeal cancer. The therapy is built upon the proprietary TransJoin™ platform, which utilizes an adeno-associated virus (AAV) vector to deliver genetic instructions that program the patient's own T cells *in vivo* to recognize and eliminate cancer cells. This approach aims to provide the potency of T-cell therapies with the delivery ease of gene therapy, bypassing the need for complex ex vivo cell manufacturing. As of early 2024, VNX-301 is in the discovery stage of development.

Targets

PSMB9 (Immunoproteasome subunit beta type-1i)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on VNX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNX-301.

Explore the full profile